Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder |
Description | Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody designed to target the TWEAK receptor (TweakR), a protein involved in various cellular responses through its interaction with its natural ligand, TWEAK (Fn14; TNFRSF12A). By directly engaging TweakR signaling and promoting antibody-dependent cell-mediated cytotoxicity (ADCC), enavatuzumab effectively inhibits tumor growth. It also recruits and activates myeloid effector cells to destroy tumor cells. Enavatuzumab has demonstrated the ability to suppress the proliferation of a range of human TweakR-positive cancer cell lines and tumorigenic models both in vitro and in vivo [1] [2]. |
Cas No. | 1062149-33-0 |
Storage |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.